Surgery remains the only potentially curative treatment for patients with gastric cancer. Curative surgery, however, can only be performed in a minority of patients who undergo surgical exploration. Even among patients who undergo radical resection, the rates of locoregional recurrence and systemic metastases remain high. In an effort to address these risks and improve the rates of tumor control and overall survival, multiple perioperative and postoperative strategies have been evaluated over the last 3 decades. The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial evaluated a regimen of epirubicin, cisplatin, and 5-fluorouracil (5-FU) given preoperatively and postoperatively compared with surgery alone in patients with esophageal/gastroesophageal and gastric cancers ( 1 x 1 Cunningham, D., Allum, W.H., Stenning, S.P. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11–20 Crossref | PubMed | Scopus (2971) | Google Scholar See all References ) (1) . Although only 42% of patients in the perioperative arm completed all protocol treatment, the perioperative-chemotherapy group had a higher likelihood of overall survival and progression-free survival than the surgery group (p = 0.009 and p < 0.001, respectively). The Intergroup Trial 0116 randomized surgically resected patients to observation vs. postoperative 5-FU, leucovorin, and 45 Gy of radiation therapy ( 2 x 2 Macdonald, J.S., Smalley, S.R., Benedetti, J. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345: 725–730 Crossref | PubMed | Scopus (2391) | Google Scholar See all References ) (2) . Multimodality therapy improved locoregional control and overall survival in gastric cancer patients after resection with microscopically negative margins (R0). Nonetheless, a significant number of patients do not qualify for this therapy because R0 resection can only be achieved in less than 50% of patients ( 3 x 3 Adashek, K., Sanger, J., and Longmire, W.P. Jr. Cancer of the stomach. Review of consecutive ten year intervals. Ann Surg. 1979; 189: 6–10 Crossref | PubMed | Scopus (101) | Google Scholar See all References , 4 x 4 Wanebo, H.J., Kennedy, B.J., Chmiel, J. et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993; 218: 583–592 Crossref | PubMed | Scopus (553) | Google Scholar See all References ).